Andy Eckert is a proven leader across multiple sectors of healthcare, including Medical Devices, HCIT and Services. Currently, Andy is the CEO of Acelity, a leading provider of innovative wound care solutions and products. Under Andy’s leadership, Acelity increased its investment in R&D and new product commercialization, resulting in an impressive acceleration of top-line growth and the recently announced pending sale to 3M Corporation. Prior to Acelity, Andy served as CEO of TriZetto, the leading enterprise software solution for commercial payors, where he sharpened the company’s strategic focus and guided TriZetto to a successful sale to Cognizant in 2014. In addition, Andy has recently served as CEO of Valence Health, an emerging leader in value-based healthcare, and Chairman and CEO of CRC Health Group, a leading behavioral health treatment provider. Earlier in his career, Andy was CEO of Eclipsys Corporation and CEO of SumTotal. He began his career at ADAC Laboratories, including four years as Chairman and CEO until its sale to Philips Medical Systems in 2000.
Andy and the Managing Partner of Grant Avenue Capital have partnered together on investments involving Acelity and TriZetto.
Andy has also served on a number of corporate boards and is currently the Chairman of Varian Medical Systems (NYSE: VAR and a Director at Becton, Dickinson and Company (NYSE: BDX). He has a Bachelor of Science in Industrial Engineering and a Master of Business Administration, both from Stanford University.